LFG
BBC icon

Larson Financial Group’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Larson Financial Group’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20
Closed -$832 – 3785
2026
Q1 		$832 Hold
20
– – ﹤0.01% 3211
2025
Q4 		$771 Buy
+20
New +$679 ﹤0.01% 3023

Other funds holding BBC

KCP
Kera Capital Partners San Jose, California $1.04B AUM 52.56% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
MCM
Militia Capital Management Austin, Texas $3.37B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Larson Financial Group's BBC Position: Q2 2026 in Review

Larson Financial Group sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q2 2026, closing a stake of 20 shares — an estimated $832 sold.

Larson Financial Group first reported a position in BBC in Q4 2025 and held it in 2 quarters. The position peaked at $832 in Q1 2026. 20 funds tracked by Wall St. Rank hold BBC as of Q2 2026.

  • Larson Financial Group reported no remaining Virtus Biotech Clinical Trials ETF position as of Q2 2026 after selling out during the quarter.
  • Larson Financial Group sold 20 Virtus Biotech Clinical Trials ETF shares in Q2 2026, an estimated $832.
  • Larson Financial Group first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2025 and held it in 2 quarters.
  • Larson Financial Group's Virtus Biotech Clinical Trials ETF position peaked at $832 in Q1 2026.
  • 20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.